<DOC>
	<DOCNO>NCT02589236</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , parallel group study . The purpose study investigate efficacy safety Cavosonstat ( N91115 ) adult patient CF homozygous F508del-CFTR mutation treat lumacaftor/ivacaftor ( Orkambi™ ) .</brief_summary>
	<brief_title>Study Cavosonstat ( N91115 ) Patients With CF Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description>Primary Objective : - Assess efficacy N91115 12 week add preexist treatment lumacaftor/ivacaftor adult patient CF homozygous F508del-CFTR mutation Secondary Objectives : - Assess effect N91115 add lumacaftor/ivacaftor safety - Assess effect lumacaftor/ivacaftor add N91115 pharmacokinetics N91115 , lumacaftor , ivacaftor</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Patients must treat lumacaftor/ivacaftor least 8 week prior Day 1 ( start dose ) A history Sweat Chloride ( SC ) ≥ 60 mEq/L quantitative pilocarpine iontophoresis test ( QPIT ) ( either start lumacaftor/ivacaftor treatment ) Body weight ≥ 40 kg ppFEV1 40 85 % predict ( inclusive ) screen Oxygen saturation ≥ 90 % breathe ambient air screen Any acute infection require treatment hospitalization within 2 week Study Day 1 Colonization organisms associate rapid decline pulmonary status , Burkholderia cenocepacia , Burkholderia dolosa , Mycobacterium abscessus Any change regimen chronic therapy CF lung disease ( e.g. , Pulmozyme® , hypertonic saline , Azithromycin , TOBI® , Cayston® ) within 4 week Study Day 1 Are pregnant , planning pregnancy , breastfeed screen Blood hemoglobin &lt; 10 g/dL screen Serum albumin &lt; 2.5 g/dL screen Abnormal liver function define ≥ 3 x upper limit normal ( ULN ) History abnormal renal function within 3 month screen History ventricular tachycardia clinically significant ventricular arrhythmia History , include screen assessment , prolong QT and/or QTcF ( Fridericia 's correction ) interval History solid organ hematological transplantation History alcohol abuse drug abuse Ongoing participation another therapeutic clinical trial Use continuous ( 24 hr/day ) nocturnal supplemental oxygen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>N91115</keyword>
	<keyword>Cavosonstat</keyword>
</DOC>